GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anatara Lifesciences Ltd (ASX:ANR) » Definitions » Return-on-Tangible-Equity

Anatara Lifesciences (ASX:ANR) Return-on-Tangible-Equity : -123.85% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Anatara Lifesciences Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Anatara Lifesciences's annualized net income for the quarter that ended in Dec. 2023 was A$-1.36 Mil. Anatara Lifesciences's average shareholder tangible equity for the quarter that ended in Dec. 2023 was A$1.10 Mil. Therefore, Anatara Lifesciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -123.85%.

The historical rank and industry rank for Anatara Lifesciences's Return-on-Tangible-Equity or its related term are showing as below:

ASX:ANR' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -176.76   Med: -39.57   Max: -7.64
Current: -134.07

During the past 9 years, Anatara Lifesciences's highest Return-on-Tangible-Equity was -7.64%. The lowest was -176.76%. And the median was -39.57%.

ASX:ANR's Return-on-Tangible-Equity is ranked worse than
79.46% of 1305 companies
in the Biotechnology industry
Industry Median: -46.56 vs ASX:ANR: -134.07

Anatara Lifesciences Return-on-Tangible-Equity Historical Data

The historical data trend for Anatara Lifesciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anatara Lifesciences Return-on-Tangible-Equity Chart

Anatara Lifesciences Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only -39.57 -76.77 -59.70 -97.50 -176.76

Anatara Lifesciences Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -73.72 -133.37 -124.24 -161.73 -123.85

Competitive Comparison of Anatara Lifesciences's Return-on-Tangible-Equity

For the Biotechnology subindustry, Anatara Lifesciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anatara Lifesciences's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anatara Lifesciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Anatara Lifesciences's Return-on-Tangible-Equity falls into.



Anatara Lifesciences Return-on-Tangible-Equity Calculation

Anatara Lifesciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-2.023/( (1.364+0.925 )/ 2 )
=-2.023/1.1445
=-176.76 %

Anatara Lifesciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-1.358/( (0.925+1.268)/ 2 )
=-1.358/1.0965
=-123.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Anatara Lifesciences  (ASX:ANR) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Anatara Lifesciences Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Anatara Lifesciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Anatara Lifesciences (ASX:ANR) Business Description

Traded in Other Exchanges
N/A
Address
c/- Perks, 81 Flinders Street, Level 8, Adelaide, SA, AUS, 5000
Anatara Lifesciences Ltd is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Its products include the Gastrointestinal ReProgramming dietary supplement (GaRP) for humans and Detach for animals. It generates its income from license revenue.

Anatara Lifesciences (ASX:ANR) Headlines

No Headlines